At this time, [Operator instructions] I will now turn the call over to your host, Mr. John Bluth at BioCryst. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; chief medical officer, Dr.
Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover here appears to be the news that the Food and Drug Administration (FDA) has lifted the partial clinical hold on BCX9930. BCX9930 is an oral Factor D inhibitor indicated for a rare blood disease known as paroxysmal nocturnal hemoglobinuria (PNH).
BioCryst (BCRX) delivered earnings and revenue surprises of 11.11% and 2.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?